Osteopore ipo, page-29

A lot Of BS on IPO Forum lately .Let me talk about this IPO instead . Following are my reasons to invest in Osteopore IPO .

Oteopore Limited is a medtech business that specializes in the production of 3D printed bioresorbable implants that are used in conjunction with surgical procedures to assist with the natural stages of bone replacement.

Osteopore currently has two products groups which are currently being sold at present,

1 ) Osteoplug

2) Osteomesh

Both products are US FDA (510k) cleared and CE Mark approved for cranial facial application.

With over $13m in research investment, grant funding and investor investment, Osteopore has successfully commercialised its technology.

The company is now revenue generating ( which is rare in micro cap MedTech space ) having been used in over 20,000 successful treatments and over the past 3 years has grown sales to nearly $1m p.a.

Osteopore has achieved a number of key milestones in recent years including:

US Food and Drug Administration (FDA) and CE-Mark approval for Osteoplug and Osteomesh products

Regulatory approval for market access obtained in US, Western Europe, Singapore, Malaysia, Vietnam, Thailand, South Korea, Taiwan, India and Pakistan

Successfully completed clinical trials for Osteoplug and Osteomesh products

Established clinical manufacturing facility in Singapore and Successful commercialisation of Osteoplug and Osteomesh.

The Company’s proprietary technology has been exclusively licensed from three of Singapore’s leading universities NTU, NUS, and Temasek Polytechnic.

Osteopore’s proprietary technology includes:

Method for Fabricating a Filament for use in Tissue Engineering ,Bioresorbable Plug Implants and Method for Bone Tissue Regeneration.

3-D Bioresorbable Scaffolds for Tissue Engineering Application

Resorbable Scaffolds for Bone Repair and Long Bone Tissue Engineering

Construction of 3-D printer micro-extruder

Algorithm to convert 3-D image to 3-D printing codes and Process parameters and quality controls.

Raising funds to expand its operations internationally and to expand its products into the orthopaedic and dental sectors.

Capital Structure :

Total SOI post IPO : 101,230,502

Existing shares : 3,953,494

Shares offered under the Consideration Offer : 71,027,008

Escrowed shares : 74,027,008

So almost all existing shares and shares under consideration offer are Escrowed.

conclusion :

Highly scalable and derisked business with all the approvals in place .Capital structure is extremely tight with most existing shares are escrowed. Very reasonably priced and left a lot on the table for IPO investors and Post IPO investors if they can get it under 50 mil Mcap ( Unlikely IMO due to highly oversubscribed and heavily scaled IPO )

IMO it should trade at $ 1 or more in 6 to 12 months post listing if they can secure some good distribution partnerships in US and Europe.

Worth mentioning Brett Sandercock is a Non-Executive Chairman of Osteopore who is a Current CFO of Resmed Limited (ASX:RMD) (ASX 100 company) 8 Bil Mcap.

Regenerative therapy sector + Customised 3D printed Products + Tight Capital structure + High caliber management + Regulatory approvals in place + Revenue Generative = Multibags potential .

Managed to get small allocations in it and I will be buying more On market depending on price .

IMO ONLY

DYOR

GLTAH